

**TABLE 185: DISCONTINUATION — ALL-CAUSE(S)**

AUTHOR, YEAR, STUDY NAME	GENOTYPE	TREATMENT	n	N	%
Afdhal et al., 2014 ION-1	1	(6) SOF12 + LDV12	2	214	1%
		(7) SOF24 + LDV24	9	217	4%
		(10) SOF12 + LDV12 + RBV12	4	217	2%
		(11) SOF24 + LDV24 + RBV24	12	217	6%
Dieterich et al., 2014-1	1	(42) SIM12 PR24-48 RGT	9	53	17%
Feld et al., 2014 SAPPHIRE-I	1	(15) PAR/RIT12 + OMB12 + DAS12 + RBV12	9	473	2%
Ferenci et al., 2014 PEARL-III	1b	(14) PAR/RIT12 + OMB12 + DAS12	1	209	0%
Ferenci et al., 2014 PEARL-IV	1a	(15) PAR/RIT12 + OMB12 + DAS12 + RBV12	0	100	0%
Fried et al., 2013 PILLAR	1	(1) PR48	10	77	13%
		(42) SIM12 PR24-48 RGT	12	77	16%
Gane et al., 2013-1 ELECTRON	2+3	(3) SOF12 + RBV12	0	10	0%
		(40) SOF12 + PR12	1	11	9%
Gane et al., 2013-3 ELECTRON	1	(3) SOF12 + RBV12	0	25	0%
Hassanein et al., 2015	4	(52) DCV12 + ASU12 + BEC12 (75 mg b.i.d.)	0	11	0%
		(53) DCV12 + ASU12 + BEC12 (150 mg b.i.d.)	0	10	0%
Jacobson et al., 2011 ADVANCE	1	(1) PR48	159	361	44%
		(32) T12 PR24-48 RGT q8	95	363	26%
Kohli et al., 2015	1	(6) SOF12 + LDV12	0	20	0%
Kowdley et al., 2014 ION-3	1	(6) SOF12 + LDV12	5	216	2%
		(8) SOF8 + LDV8	0	215	0%
		(9) SOF8 + LDV8 + RBV8	3	216	1%
Kowdley et al., 2013 ATOMIC	1	(40) SOF12 + PR12	5	52	10%
Kumada et al., 2014	1b	(17) DCV24 + ASU24	14	135	10%
Lalezari et al. et al., 2015	1	(15) PAR/RIT12 + OMB12 + DAS12 + RBV12	1	38	3%
Lawitz et al., 2013 NEUTRINO	1+4+5+6	(40) SOF12 + PR12	7	327	2%
Lawitz et al., 2013 FISSION	2+3	(3) SOF12 + RBV12	11	256	4%
		(70) PR24	54	243	22%
Lawitz et al., 2014 LONESTAR	1	(6) SOF12 + LDV12	1	19	5%
		(8) SOF8 + LDV8	0	20	0%
		(9) SOF8 + LDV8 + RBV8	0	21	0%
Lawitz et al., 2013 PROTON-1	1	(1) PR48	11	26	42%
		(41) SOF12 PR24-48 RGT	5	47	11%
Lawitz et al., 2013 PROTON-2	2+3	(40) SOF12 + PR12	1	25	4%
Manns et al., 2014 HALLMARK-DUAL	1b	(17) DCV24 + ASU24	15	205	7%
Manns et al., 2014 QUEST-2	1	(1) PR48	53	134	40%
		(42) SIM12 PR24-48 RGT	22	257	9%

AUTHOR, YEAR, STUDY NAME	GENOTYPE	TREATMENT	n	N	%
Marcellin et al., 2011	1	(32) T12 PR24-48 RGT q8	14	82	17%
		(33) T12 PR24-48 RGT q12	19	79	24%
Mizokami et al. et al., 2015	1	(6) SOF12 + LDV12	0	83	0%
		(10) SOF12 + LDV12 + RBV12	2	83	2%
Molina et al., 2015-1 PHOTON-2	1	(4) SOF24 + RBV24	6	112	5%
Molina et al., 2015-2 PHOTON-2	2	(3) SOF12 + RBV12	0	19	0%
Molina et al., 2015-3 PHOTON-2	3	(4) SOF24 + RBV24	3	57	5%
Molina et al., 2015-4 PHOTON-2	4	(4) SOF24 + RBV24	0	31	0%
Muir et al. et al., 2015 UNITY-2	1+6	(25) DCV12 + ASU12 + BEC12 + RBV12	0	55	0%
		(26) DCV12 + ASU12 + BEC12	0	57	0%
Nelson D. et al., 2015 ALLY-3	3	(19) DCV12 + SOF12	0	101	0%
Omata et al., 2014	2	(3) SOF12 + RBV12	0	90	0%
Osinusi et al., 2013 SPARE-1	1	(4) SOF24 + RBV24	1	10	10%
Osinusi et al., 2013 SPARE-2	1	(4) SOF24 + RBV24	2	25	8%
		(71) SOF24 + RBV (low dose) 24	3	25	12%
Osinusi et al., 2015	1	(6) SOF12 + LDV12	0	50	0%
Poordad et al., 2011 SPRINT2	1	(1) PR48	204	363	56%
		(46) B24 PR28-48 RGT	139	368	38%
Poordad et al. et al., 2015 UNITY-1	1	(26) DCV12 + ASU12 + BEC12	7	312	2%
Sulkowski et al., 2014-1	2+3	(3) SOF12 + RBV12	3	26	12%
Sulkowski et al., 2014-2	1	(4) SOF24 + RBV24	11	115	10%
Sulkowski et al., 2014	1	(19) DCV12 + SOF12	0	41	0%
Sulkowski et al., 2013-1	1	(1) PR48	4	6	67%
		(39) T12 PR48 q8	3	7	43%
Sulkowski et al., 2013-2	1	(1) PR48	2	8	25%
		(39) T12 PR48 q8	7	15	47%
Sulkowski et al., 2013	1	(1) PR48	23	34	68%
		(50) B44 PR48	24	64	38%
Zeuzem et al., 2015 C-EDGE	1+4+6	(22) GRZ12 + ELB12	5	316	2%

ASU = asunaprevir; B = boceprevir; BEC = beclabuvir; b.i.d. = twice daily; CrI = credible interval; DAS = dasabuvir; DCV = daclatasvir; ELB = elbasvir; GRZ = grazoprevir; LDV = ledipasvir; OMB = ombitasvir; PAR = paritaprevir; PR = pegylated interferon plus ribavirin; q8 = every 8 hours; q12 = every 12 hours; RBV = ribavirin; RD = risk difference; RGT = response-guided therapy; RIT = ritonavir; RR = relative risk; SIM = simeprevir; SOF = sofosbuvir; SVR = sustained virologic response; T = telaprevir; vs. = versus.  
Note: Please refer to Treatment Regimen Nomenclature table for description of dosages.